RC98
RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys (half female and half male)[1]
-
Dosage:15 mg/kg
-
Administration:i.v.; once weekly; 4 weeks
-
Result:Reached a mean peak PD-L1 receptor occupancy of 64.5% on CD3+ T cells within 24 h after the first infusion.
Showed reduced receptor occupancy after repeated dosing but maintained levels above background throughout testing.
Elevated anti-KLH IgM levels versus controls at 168 h, 336 h, and 504 h post-first dose.
Increased anti-KLH IgG levels versus controls at multiple time points post-first and last doses.
Induced sustained elevation of soluble PD-L1 with a strong correlation to serum RC98 concentrations.
Parmacokinetics
Target
B7-H1/PD-L1/CD274
Application
ELISA, FACS, Functional assay
Product Details
Product Properties
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)